1086 related articles for article (PubMed ID: 24210082)
1. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
3. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
[TBL] [Abstract][Full Text] [Related]
4. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
[TBL] [Abstract][Full Text] [Related]
6. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size.
Marwaha G; Stephans KL; Woody NM; Reddy CA; Videtic GM
J Thorac Oncol; 2014 Nov; 9(11):1693-7. PubMed ID: 25185531
[TBL] [Abstract][Full Text] [Related]
7. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.
Park HS; Harder EM; Mancini BR; Decker RH
J Thorac Oncol; 2015 May; 10(5):832-837. PubMed ID: 25634007
[TBL] [Abstract][Full Text] [Related]
8. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
[TBL] [Abstract][Full Text] [Related]
10. [An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].
Guillerme F; Clavier JB; Schumacher C; Falcoz PE; Bourrhala K; Santelmo N; Hassler S; Schott R; Quoix E; Massard G; Noël G
Cancer Radiother; 2013; 17(4):272-81. PubMed ID: 23712043
[TBL] [Abstract][Full Text] [Related]
11. Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection.
Hayes JT; David EA; Qi L; Chen AM; Daly ME
Clin Lung Cancer; 2015 Sep; 16(5):379-84. PubMed ID: 25737143
[TBL] [Abstract][Full Text] [Related]
12. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
13. Excellent Cancer Outcomes Following Patient-adapted Robotic Lung SBRT But a Case for Caution in Idiopathic Pulmonary Fibrosis.
Bahig H; Filion E; Vu T; Roberge D; Lambert L; Bouchard M; Lavoie C; Doucet R; Nadeau DB; Chalaoui J; Campeau MP
Technol Cancer Res Treat; 2015 Dec; 14(6):667-76. PubMed ID: 24988054
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.
Temming S; Kocher M; Stoelben E; Hagmeyer L; Chang DH; Frank K; Hekmat K; Wolf J; Baus WW; Semrau R; Baues C; Marnitz S
Strahlenther Onkol; 2018 Feb; 194(2):91-97. PubMed ID: 28812120
[TBL] [Abstract][Full Text] [Related]
17. Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.
Hearn JW; Videtic GM; Djemil T; Stephans KL
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):402-6. PubMed ID: 25017480
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
20. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
